ClinicalTrials.gov Identifier: NCT04305002.

Study name	Effect of exenatide on disease progression in early Parkinson’s disease
Methods	Single‐centre, double‐blind, placebo‐controlled study
Participants	Early stages of PD
Interventions	Intervention: exenatide 2mg once weekly for 18 months Comparison: placebo once weekly for 18 months
Outcomes	Primary: FDG‐PET analysis Secondary: MDS‐UPDRS part 3 in OFF medication state
Starting date	January 2020
Contact information	per.svenningsson@ki.se
Notes

GLP1R: glucagon‐like peptide‐1 receptor.

MDS‐UPDRS: Movement Disorder Society‐Unified Parkinson's Disease Rating Scale.

PD: Parkinson's disease.